Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $24.82 up 0.89% from its previous closing price of $24.6. In other words, the price has increased by $0.89 from its previous closing price. On the day, 1.8 million shares were traded. ACAD stock price reached its highest trading level at $24.85 during the session, while it also had its lowest trading level at $24.365.
Ratios:
For a deeper understanding of Acadia Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.38. For the most recent quarter (mrq), Quick Ratio is recorded 2.83 and its Current Ratio is at 2.91. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 04 ’25 when Brege Laura sold 14,446 shares for $21.78 per share. The transaction valued at 314,634 led to the insider holds 15,095 shares of the business.
LAURA BREGE bought 14,446 shares of ACAD for $314,638 on Jun 04 ’25. On May 16 ’25, another insider, Kihara James, who serves as the PRINCIPAL ACCOUNTING OFFICER of the company, sold 4,000 shares for $22.50 each. As a result, the insider received 90,000 and left with 20,395 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 4187431680 and an Enterprise Value of 3481735424. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.65, and their Forward P/E ratio for the next fiscal year is 30.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.11 while its Price-to-Book (P/B) ratio in mrq is 5.09. Its current Enterprise Value per Revenue stands at 3.417 whereas that against EBITDA is 33.489.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.75, which has changed by 0.5778767 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $25.23, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is 10.63%, while the 200-Day Moving Average is calculated to be 33.83%.
Shares Statistics:
For the past three months, ACAD has traded an average of 2.13M shares per day and 1808940 over the past ten days. A total of 168.61M shares are outstanding, with a floating share count of 166.90M. Insiders hold about 1.07% of the company’s shares, while institutions hold 101.53% stake in the company. Shares short for ACAD as of 1752537600 were 11478190 with a Short Ratio of 5.39, compared to 1749772800 on 15435884. Therefore, it implies a Short% of Shares Outstanding of 11478190 and a Short% of Float of 10.8.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 13.0 analysts currently analyzing and rating the stock of Acadia Pharmaceuticals Inc (ACAD).The consensus estimate for the next quarter is $0.13, with high estimates of $0.27 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.76 and $0.42 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.86, with 14.0 analysts recommending between $1.93 and $0.17.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $276.52M this quarter.It ranges from a high estimate of $291.06M to a low estimate of $271.8M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $250.4MFor the next quarter, 17 analysts are estimating revenue of $286.69M. There is a high estimate of $306.5M for the next quarter, whereas the lowest estimate is $278.8M.
A total of 19 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.06B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $957.8MBased on 18 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.33B and the low estimate is $1.13B.
